Physician profile
John Kingrey
NPI 1689863953
$332,177.95
in general payments reported to CMS, 2019-2025
24 companies · $49K in 2025
The $49K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $24K · 2021: $38K · 2022: $60K · 2023: $60K · 2024: $62K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Consulting Fee: $47K · Travel and Lodging: $15K · Food and Beverage: $7,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,287.00 |
| Consulting Fee | $46,653.75 |
| Travel and Lodging | $14,974.73 |
| Food and Beverage | $7,706.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $164,372.76 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $112,062.68 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Merck Sharp & Dohme LLC | $28,728.01 | 2023-2025 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $25,418.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.77 | 2020-2025 | Ofev |
| Sandoz INC. | $214.51 | 2019-2023 | Treprostinil |
| Novo Nordisk INC | $194.99 | 2022 | |
| Abbott Laboratories | $163.94 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Insmed, INC. | $158.87 | 2019-2023 | Arikayce |
| Genentech USA, INC. | $150.98 | 2019 | |
| Abiomed | $77.06 | 2022 | |
| Inogen, INC. | $51.52 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Glaxosmithkline, LLC. | $39.79 | 2023-2025 | Trelegy Ellipta, Nucala |
| Kestra Medical Technology Services, INC. | $39.23 | 2024 | Assure Wcd |
| Johnson & Johnson Health Care Systems INC. | $28.07 | 2023 | Opsumit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.40 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.31 | 2022 | |
| Amgen INC. | $20.91 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.20 | 2024 | Onpattro |
| Veran Medical Technologies, INC. | $14.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.27 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.02 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kingrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.